Phase 2 Study of aTezolizumab, bevAcizumab, and Cobinetinib (TACo) in patients (pts) with PD1 refractory metastatic brain metastases (MBM)

• E. Burton,
• V. Honaker,
• D. Milton,
• I. Glitza,
• R. Amaria,
• S. Patel,
• A. Diab,
• M. Wong,
• J. McQuade,
• C. Chung,
• J. Wefel,
• J. Li,
• M. Davies,
• H. Tawbi

Affiliations

E. Burton

University of Texas MD Anderson Cancer Center, Melanoma Medical Oncology, Houston, United States of America

V. Honaker

University of Texas MD Anderson Cancer Center, Melanoma Medical Oncology, Houston, United States of America

D. Milton

University of Texas MD Anderson Cancer Center, Melanoma Medical Oncology, Houston, United States of America

I. Glitza

University of Texas MD Anderson Cancer Center, Melanoma Medical Oncology, Houston, United States of America

R. Amaria

University of Texas MD Anderson Cancer Center, Melanoma Medical Oncology, Houston, United States of America

S. Patel

University of Texas MD Anderson Cancer Center, Melanoma Medical Oncology, Houston, United States of America

A. Diab

University of Texas MD Anderson Cancer Center, Melanoma Medical Oncology, Houston, United States of America

M. Wong

University of Texas MD Anderson Cancer Center, Melanoma Medical Oncology, Houston, United States of America

J. McQuade

University of Texas MD Anderson Cancer Center, Melanoma Medical Oncology, Houston, United States of America

C. Chung

University of Texas MD Anderson Cancer Center, Melanoma Medical Oncology, Houston, United States of America

J. Wefel

University of Texas MD Anderson Cancer Center, Melanoma Medical Oncology, Houston, United States of America

J. Li

University of Texas MD Anderson Cancer Center, Melanoma Medical Oncology, Houston, United States of America

M. Davies

University of Texas MD Anderson Cancer Center, Melanoma Medical Oncology, Houston, United States of America

H. Tawbi

University of Texas MD Anderson Cancer Center, Melanoma Medical Oncology, Houston, United States of America